The stock market was relatively quiet on Thursday, with the Dow Jones Industrial Average pushing higher alongside the other major benchmarks. Large-cap stocks outperformed small caps as investors seemed to get more comfortable about the trade issues affecting multinational corporations. Company-specific events made headlines, and Advanced Micro Devices (NASDAQ: AMD), Ciena (NYSE: CIEN), and Eloxx Pharmaceuticals (NASDAQ: ELOX) were among the top performers. Here's why they did so well.
Morgan Stanley says "no mas" on negative AMD call
Shares of Advanced Micro Devices climbed 8% in the wake of an upgrade from a major Wall Street stock analysis company. Morgan Stanley reversed its previous views on the graphics processing chipmaker, boosting its rating on AMD from underweight to equal weight and pushing its price target up by $11 to $28 per share. Even in the upgrade, Morgan Stanley remained somewhat petulant, arguing that there's too much short-term thinking supporting the stock. Yet in the absence of obvious reasons to be negative about the chipmaker's prospects, analysts admitted that they'd been wrong in the wake of the stock's huge gains, and shareholders liked what they saw in the capitulation.
Image source: AMD.
Ciena makes a smooth connection
Ciena's stock soared 27% after the optical networking specialist reported its fiscal second-quarter financial results. Revenue climbed almost 19% from the year-ago period, and adjusted net income more than doubled as demand from two major customers helped lift numbers in Ciena's networking platforms, software, and global services businesses. The company also sees favorable conditions persisting for the remainder of the year, and as CEO Gary Smith put it, Ciena has "strong visibility and increased confidence for the full fiscal year supported by favorable industry dynamics and growing competitive advantage." That bodes well for the company's prospects for the foreseeable future.
Eloxx makes progress
Finally, shares of Eloxx Pharmaceuticals jumped 10%. The clinical-stage biopharmaceutical company released data from its investigation of its ELX-02 candidate treatment showing that it resulted in restored activity for a key cystic fibrosis transmembrane conductance regulator protein. Several oral presentations went through early conclusions, which included that ELX-02 was well-tolerated by patients in general along with other favorable findings. Eloxx expects to report data from a phase 2 study of ELX-02 in cystic fibrosis patients later in 2019. Having faced tough times recently, Eloxx investors hope that this will translate into further progress toward eventual approval of a treatment for the disease.
More From The Motley Fool
- 10 Best Stocks to Buy Today
- The $16,728 Social Security Bonus You Cannot Afford to Miss
- 20 of the Top Stocks to Buy (Including the Two Every Investor Should Own)
- What Is an ETF?
- 5 Recession-Proof Stocks
- How to Beat the Market